Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gatifloxacin

FDA-approved product (solution/drops, ophthalmic), marketed as Gatifloxacin, Zymar, Zymaxid.

Registered studies
39
Lab records
43
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Gatifloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Eye infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA16; WHO ATC S01AE06

Repurposing investigation

Gatifloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae90.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 3 of 3 lab records
  • E. coli: measured active in 5 of 5 lab records
  • K. pneumoniae: measured active in 14 of 14 lab records
  • M. tuberculosis: measured active in 21 of 21 lab records
Open Gatifloxacin in ChEMBL Registered studies below
Show the 43 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gatifloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

    NCT00874887 · start 2009-03

    Registered record
    Registry ID
    NCT00874887
    Conditions
    Anti-biotic Resistance
    Interventions
    moxifloxacin 0.5% HCI ophthalmic solution; gatifloxacin ophthalmic solution 0.3%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2009-10
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti-biotic Resistance
    Interventionmoxifloxacin 0.5% HCI ophthalmic solution; gatifloxacin ophthalmic solution 0.3%
    PhasePhase 4
    Registry statusCompleted

  • Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

    NCT00905762 · start 2009-03

    Registered record
    Registry ID
    NCT00905762
    Conditions
    Healthy
    Interventions
    Gatifloxacin; Moxifloxacin; Besifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03
    Completion
    2009-04
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGatifloxacin; Moxifloxacin; Besifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

    NCT00824070 · start 2009-02

    Registered record
    Registry ID
    NCT00824070
    Conditions
    Cataract Extraction
    Interventions
    Besifloxacin hydrochloride; moxifloxacin hydrochloride; gatifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2009-08
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract Extraction
    InterventionBesifloxacin hydrochloride; moxifloxacin hydrochloride; gatifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics

    NCT00831961 · start 2009-01

    Registered record
    Registry ID
    NCT00831961
    Conditions
    Age-related Macular Degeneration
    Interventions
    Conjunctival and nasopharyngeal bacteria cultures
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-01
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAge-related Macular Degeneration
    InterventionConjunctival and nasopharyngeal bacteria cultures
    PhaseNot recorded
    Registry statusCompleted

  • Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation

    NCT01218737 · start 2009-01

    Registered record
    Registry ID
    NCT01218737
    Conditions
    Ocular Infection and Inflammation
    Interventions
    0.3% gatifloxacin and 1.0% prednisolone acetate association; isolated 0.3% gatifloxacin and 1.0% prednisolone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-06
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Infection and Inflammation
    Intervention0.3% gatifloxacin and 1.0% prednisolone acetate association; isolated 0.3% gatifloxacin and 1.0% prednisolone acetate
    PhasePhase 3
    Registry statusCompleted

  • Topical Antibiotics and Intravitreous Injections

    NCT00410891 · start 2008-07

    Registered record
    Registry ID
    NCT00410891
    Conditions
    Intravitreous; Injections
    Interventions
    gatifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07
    Completion
    2009-12
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntravitreous; Injections
    Interventiongatifloxacin
    PhasePhase 4
    Registry statusCompleted

  • Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

    NCT00703313 · start 2008-05

    Registered record
    Registry ID
    NCT00703313
    Conditions
    Healthy
    Interventions
    1.5% levofloxacin ophthalmic solution; 0.5% moxifloxacin hydrochloride ophthalmic solution; 0.3% gatifloxacin ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention1.5% levofloxacin ophthalmic solution; 0.5% moxifloxacin hydrochloride ophthalmic solution; 0.3% gatifloxacin ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

    NCT00518089 · start 2008-02

    Registered record
    Registry ID
    NCT00518089
    Conditions
    Bacterial Conjunctivitis
    Interventions
    Gatifloxacin 0.5% eye drops; placebo eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-01
    Enrolment
    859

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Conjunctivitis
    InterventionGatifloxacin 0.5% eye drops; placebo eye drops
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

    NCT00509873 · start 2007-08

    Registered record
    Registry ID
    NCT00509873
    Conditions
    Bacterial Conjunctivitis
    Interventions
    Gatifloxacin 0.5% eye drops; placebo eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-08
    Completion
    2008-06
    Enrolment
    578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Conjunctivitis
    InterventionGatifloxacin 0.5% eye drops; placebo eye drops
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

    NCT00464438 · start 2007-06

    Registered record
    Registry ID
    NCT00464438
    Conditions
    Bacterial Conjunctivitis
    Interventions
    gatifloxacin; moxifloxacin 0.5% eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2008-09
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Conjunctivitis
    Interventiongatifloxacin; moxifloxacin 0.5% eye drops
    PhasePhase 4
    Registry statusCompleted

  • Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application

    NCT00466570 · start 2007-04

    Registered record
    Registry ID
    NCT00466570
    Conditions
    Conjunctical Flora
    Interventions
    gatifloxacin, moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2007-04
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctical Flora
    Interventiongatifloxacin, moxifloxacin
    PhaseNot applicable
    Registry statusWithdrawn

  • One Hour Preoperative Gatifloxacin

    NCT00350363 · start 2007-01

    Registered record
    Registry ID
    NCT00350363
    Conditions
    Ophthalmic Surgery
    Interventions
    Zymar
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2010-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOphthalmic Surgery
    InterventionZymar
    PhasePhase 4
    Registry statusCompleted

  • Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK

    NCT00569881 · start 2007-01

    Registered record
    Registry ID
    NCT00569881
    Conditions
    Corneal Epithelial Wound Healing
    Interventions
    gatifloxacin and moxifloxacin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-03
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Epithelial Wound Healing
    Interventiongatifloxacin and moxifloxacin
    PhaseNot recorded
    Registry statusCompleted

  • Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery

    NCT00335231 · start 2006-06

    Registered record
    Registry ID
    NCT00335231
    Conditions
    Endophthalmitis
    Interventions
    gatifloxacin ophthalmic (ZYMAR)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2006-06
    Completion
    2013-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndophthalmitis
    Interventiongatifloxacin ophthalmic (ZYMAR)
    PhaseNot applicable
    Registry statusWithdrawn

  • Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

    NCT00347828 · start 2006-06

    Registered record
    Registry ID
    NCT00347828
    Conditions
    Eye Infection; Infection
    Interventions
    Moxifloxacin ophthalmic solution 0.5%; Gatifloxacin ophthalmic solution 0.3%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2006-06
    Completion
    2006-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEye Infection; Infection
    InterventionMoxifloxacin ophthalmic solution 0.5%; Gatifloxacin ophthalmic solution 0.3%
    PhasePhase 4
    Registry statusUnknown